Efficacy of rapamycin in scleroderma: A case study

Lymphatic Research and Biology

Volumn 6, Issue 3-4, 2008, Pages 217-219

  Fried, Levi ^b   Kirsner, Robert S ^b   Bhandarkar, Sulochana ^b   Arbiser, Jack L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CELL TRANSFORMATION; CLINICAL FEATURE; COLLAGEN SYNTHESIS; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; SCLERODERMA;

ADULT; ANGIOGENESIS INHIBITORS; COLLAGEN; FEMALE; FIBROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MESODERM; PREGNANCY; PREGNANCY COMPLICATIONS; SCLERODERMA, SYSTEMIC; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 58149096523     PISSN: 15396851     EISSN: None     Source Type: Journal    
DOI: 10.1089/lrb.2008.1006     Document Type: Article

References (10)

1. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hse VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler R, Rothfield N, Metersky M, Clements RJ, Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007;56:1676-1684.
2. Connolly MK, McCalmont TH. Fetal DNA and cells in women with systemic sclerosis. N Engl J Med 1998;339:771-772.
3. Zhang Y, Gilliam AC. Animal models for scleroderma: an update. Curr Rheumatol Rep 2002;4:150-162.
4. Askew D, Zhou L, Wu C, Chen G, Gilliam AC. Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007;127:1905-1914.
5. Aliprantis AO, Wang J, Fathman JW, Lemaire R, Dorfman DM, Lafyatis R, Glimcher H. . Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA 2007;104:2827-2830.
6. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, Jablonska S, Blaszczyk M, Watson DK, Trojanowska M. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003;163:571-581.
7. Asano Y, Czuwara J, Trojanowska M. Transforming growth factor regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007;282:34672-34683.
8. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954-966.
9. Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol 2005;52(2 Suppl 1):17-19.
10. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:12319-12324.